SOURCE: GeneThera


September 22, 2009 08:00 ET

GeneThera Finalizes License and Research Agreement With Two Leading Italian Universities; Agreement Represents Key Step in Effort to Commercialize Diagnostic and Therapeutic Solutions for Johne's Disease

ARVADA, CO--(Marketwire - September 22, 2009) - GeneThera, Inc. (PINKSHEETS: GTHR), an international biotechnology company, today announced it has finalized a license and research agreement with two Italian universities: Universita di Roma "Tor Vergata" (UNIROMA2) and Universita Cattolica del Sacro Cuore (UCSC).

The agreement will enable GeneThera to commence therapeutic testing of a breakthrough new compound developed by the universities. The compound, called LIPOSTIM, will be tested as a possible therapy against veterinary mycobacterial disorders such as Johne's disease, an infectious, fatal and as yet incurable bacterial ailment that affects the intestinal tract in livestock and may be linked to Irritable Bowel Syndrome (IBS) and Crohn's disease in humans.

Dr. Tony Milici, founder and CEO of GeneThera, said, "LIPOSTIM is at the heart of a potentially breakthrough treatment for Johne's disease, which has become a costly and expanding problem for the global agriculture, livestock and dairy industries. LIPOSTIM acts like a 'smart bomb,' and is able to significantly enhance antimycobacterial innate immune response while simultaneously limiting tissue damage. We believe this compound will provide us with a distinct competitive advantage, as to our knowledge no comparable type of therapy exists or is being tested."

Maurizio Fraziano, a professor of immunology at UNIROMA2, and Marco De Spirito, a professor of Physics at UCSC, jointly stated, "Our universities have been collaborating for more than a decade on the development of the LIPOSTIM compound, and we are excited that GeneThera will soon commence the field testing of this potentially breakthrough therapy. We look forward to working closely with the company on these critical next steps."

Milici said the license agreement represents an important advancement in GeneThera's broader efforts to commercialize both a diagnostic and therapeutic solution to Johne's and related diseases. As previously announced, GeneThera also is working in collaboration with the Universidad Nacional Autonoma de Mexico (UNAM) on a diagnostic test for Johne's disease. UNAM will support this effort in part by providing access to livestock at a forthcoming testing facility in Monterrey, Mexico. GeneThera also has reached an agreement with Roche Diagnostics, which will provide specialized equipment for the testing.

"Our next step will be the setup of our testing lab and related infrastructure in Monterrey, and I will personally oversee these efforts," Milici said. "The LIPOSTIM clinical trial is scheduled to begin soon thereafter."

Milici added that GeneThera is working to secure additional capital required to advance its current programs, and has been in discussions with the funding arm of the New Jersey-based Pharma Finance Conference, which was recently attended by GeneThera.

Leonardo Zangani, president of New Jersey based Zangani Investment Community and organizer of Pharma Finance Conference series, stated, "As it happens in every edition of Pharma Finance, we can see positive results both at the scientific and financial levels. The agreement between GeneThera, UNIROMA2 and UCSC is an example of this success."

About GeneThera, Inc.

GeneThera, Inc. is a biotechnology company focused on the development of molecular assays. The Company is currently in the process of developing therapeutic vaccines for the detection and prevention of food contaminating pathogens, veterinary diseases, and diseases affecting human health. More information about the Company can be found at:

Safe Harbor Statement

Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Federal Private Securities Litigation Reform Act of 1995, including statements regarding the potentially breakthrough treatment for Johne's disease; the potential link between Johne's disease Irritable Bowel Syndrome (IBS) and Crohn's disease in humans; the likelihood that our diagnostic testing program will be successful; the benefits, if any, of our testing programs to the global dairy and livestock industries; the anticipated setup of our testing lab and related infrastructure in Monterrey, and Dr. Milici's personal attention to the oversight of these efforts. Forward-looking statements involve known and unknown risks and uncertainties, which may cause the Company's actual results in future periods to differ materially from forecasted results. Factors that could cause or contribute to such differences include, but are not limited to, our ability to raise capital, our ability to execute our business strategy in a very competitive environment, our degree of financial leverage, risks relating to rapidly developing technology, regulatory considerations, risks related to international economies, risks related to market acceptance and demand for our products and services, the impact of competitive services and pricing, and other risks referenced from time to time in our SEC filings. All subsequent written and oral forward-looking statements attributable to us, or anyone acting on our behalf, are expressly qualified in their entirety by these cautionary statements. We do not undertake any obligations to publicly release any revisions to any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect unanticipated events that may occur.

Contact Information


    Dr. Tony Milici
    GeneThera, Inc.

    Geoff High
    Pfeiffer High Investor Relations, Inc.